The trade media are often considered second fiddle to the buzzier top-tier outlets, but they are by no means less important to your overall earned media strategy. After 27 years working in the life sciences industry, the Bioscribe team has seen time and time again how this kind of targeted exposure is a perfect complement to the higher-profile articles placed in the top-tier media, allowing you to sustain momentum and credibility among key decision-makers and influencers. Read more about the 5 reasons why we believe that trade journalists, with their deeper understanding of the industry’s inner workings, can provide sophisticated and nuanced coverage that resonates with the often skeptical life science-focused audiences. #PR #MediaRelations #SciComms #BiotechPR #LifeSciencePR
关于我们
Bioscribe was founded in 1997 in the San Francisco Bay Area to support the area's growing biotechnology industry. For more than two decades, we have worked with companies that powered the Human Genome Project and cutting-edge start-ups that are innovating to unlock its value. We've helped launch first, second and third generation DNA sequencing systems, gene expression tools, bioinformatics software, single cell analysis solutions, molecular diagnostics, DNA forensics systems, next-generation therapies, and vaccines. We are a virtual office, with senior consultants on the West and East Coasts who bring decades of experience and expertise in the biotechnology, molecular diagnostics, pharma, and life science research markets. In addition to previous large agency experience, some of our team members have built and run in-house communications teams, and have covered the industry as journalists and editors of leading publications. If you need help telling your great story, we'd love to talk to you.
- 网站
-
https://www.bioscribe.com
Bioscribe的外部链接
- 所属行业
- 公共关系和沟通服务
- 规模
- 11-50 人
- 总部
- Healdsburg,California
- 类型
- 私人持股
- 创立
- 1997
- 领域
- Public Relations、Corporate Communications、Marketing Communications、Biotechnology、Genomics、Science Writing、Molecular Diagnostics、Content Marketing、Thought Leadership、Media Relations、Social Media Strategy、Lead Generation、Media Training和Crisis Communications
地点
-
主要
US,California,Healdsburg,95448
Bioscribe员工
-
Nicole Litchfield
CEO of Bioscribe, Inc. - Life Sciences Communications Agency
-
Andrew Noble
Marketing and Communications
-
Nancie Steinberg
Strategic Healthcare Integrated Marketing Communications Executive | Public Relations | Global Media Relations Professional | Pharma & Biotech | Life…
-
Tim Ingersoll
Life Science Communications Consultant
动态
-
Complex DNA is, in a word, complex. This excellent primer from Ansa co-founder & CSO, Dan Lin-Arlow, breaks it down and highlights how enzymatic DNA synthesis is paving the way forward for the complex DNA that is essential to driving innovation in the bioeconomy. #SynBioBeta2024 #InnovativeClients
For even the most bread-and-butter synthetic biology pursuits, having the ability to test as many types of candidate DNA sequences as possible is key. But there's one big constraint: obtaining synthetic DNA. Learn how Ansa is addressing the biggest pain points facing DNA synthesis in this SynBioBeta article by founder Daniel Lin-Arlow. https://lnkd.in/eb2Q_kqf ?? Want to find out even more? Be sure to check in with us at #SynBioBeta2024 next week. Our new CEO, Jason T. Gammack, will be taking the main stage to talk about our new enzymatic DNA synthesis method which overcomes the restrictions inherent to legacy methods in order to reliably assemble complex sequences. We'll also be joining several panels, and showcasing some of the amazing science that has been made possible by our #Ansamers in the hands of several early access customers. ?? Stay tuned for updates (including pop-up talks at Booth 312), or visit https://lnkd.in/gy_HmihZ to learn more about our Early Access Program.? #DNAsynthesis #longDNA #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #customDNA #AnsamerAnswers
The Next Frontier in Gene Synthesis: Conquering Complex DNA - SynBioBeta
synbiobeta.com
-
Bioscribe转发了
PR tip: Don't forget to showcase your company's small wins between big milestones ? Read more PR perspectives from Nicole Litchfield, CEO and founder of our partners at Bioscribe, in the latest issue of The Pitch: https://lnkd.in/gnyPWtiA
-
Today we announced a partnership with s2s Public Relations, based in Seattle. From first working together on a co-marketing campaign seven years ago, to our new partnership announced today, it’s been a pleasure getting to know Eric Schudiske and his team. For more than 25 years, Bioscribe has been a trusted partner to the life sciences startup community, and advisor to founders, CEOs, VCs, commercial teams, and comms leaders who are shaping the future of innovation and the bioeconomy. We are excited about our new partnership with s2s because it broadens our bench with new talent and capabilities in ways that will benefit our individual and shared clients, as well as our teams! #teamwork #entrepreneurship #lifescience #scicomms #biotechPR
Building community and fostering collaboration are cornerstones of the value we aim to deliver to our clients and our wider innovation ecosystem. We seek to bring together the brightest, most strategic minds to accelerate the impact of novel science and technology. To support and expand this effort, s2s has partnered with Bay Area-based life sciences PR agency Bioscribe for select life sciences clients to bring the industry's most talented communications practitioners to startups on flexible terms that meet their needs.? Learn more about this partnership and hear PR perspectives from Bioscribe's CEO, Nicole Litchfield, in our latest issue of The Pitch ?
Announcing a new partnership | Showcasing “small victories” + beating AI hype
s2s Public Relations,发布于领英
-
Thanks to Dani Stoltzfus and William Riedl at Mighty Spark Communications for hosting an engaging conversation with Bioscribe EVP Colin Sanford about when to consider the help of professional PR counsel.? It's a question we get often, and one we are always happy to discuss. In a nutshell, the decision to enlist help extends beyond an approaching milestone. It's about strategically orchestrating your PR and communications programs to align with your near-term goals while fostering a platform for building and maintaining ongoing momentum for your long-term vision. If you're seeking support for the first time, or looking for ways to expand your existing PR and communications programs, please reach out for a free consultation. We'd be happy to share our perspectives on strategies that will help you successfully engage with all of your audiences today, and into the future.? #biotechpr #lifesciencePR #scicomms #publicrelations #biotech
Colin Sanford of Bioscribe is a biotech PR expert, join us as he discusses the importance of on-boarding a comms team early and growing that relationship to ensure?your well-executed communication strategy can drive scientific innovation to transformative change. https://lnkd.in/e42ZZw23
Ep. 6 Colin Sanford Building a Rewarding Relationship With Your Comms Team
https://spotify.com
-
Big congratulations to the Synthego & EditCo teams on this industry-advancing milestone that will further accelerate innovation in the discovery and development of cell and gene therapies! #CRISPR #LifeSciences #Biotech #SciComm #CoolClients
Split Decision: Synthego Spins Out EditCo Bio Around Engineered Cell Platform Don't miss Jonathan D. Grinstein, PhD's exclusive coverage. Craig Christianson replaces founder Paul Dabrowski as CEO to focus the company’s efforts on enabling #CRISPR therapeutics, while former Synthego Corporation President and COO John Tan takes the helm at EditCo to develop #CRISPR-based research tools.
Split Decision: Synthego Spins Out EditCo Bio Around Engineered Cell Platform
genengnews.com
-
Team Bonum Therapeutics has an incredible track record in biopharmaceutical dealmaking. In this insightful perspective, Chief Business Officer Neela Patel shares advice on navigating win-win negotiations that get you to the deal you want! #ThoughtLeadership #SmartClients
Meeting investors', buyers', and sellers' goals isn't easy. Bonum's Chief Business Officer Neela Patel offers advice on how to negotiate a winning deal that leaves all parties positioned for success. Check out her insights in the Spring 2024 Issue of Drug Discovery World, starting on page 62: https://lnkd.in/gjdARyER
-
Congratulations to long-time Bioscribe client and friend Jason T. Gammack who has been appointed CEO of Ansa Biotechnologies, Inc.. Ansa is developing a new way to synthesize DNA that overcomes the limitations of traditional DNA synthesis methods to enable innovation across biologic therapeutics such as antibodies, gene therapies, and cell therapies, as well as the biomanufacturing of chemicals, materials, foods, and biofuels. https://lnkd.in/gQDUYqUu #CoolScience #AwesomeClients
Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences
https://ansabio.com
-
In this Biocompare piece, client ATUM talks about how they leverage machine learning to power a directed engineering approach that enables them to determine the relationship between protein sequence and properties of interest and then use those insights to drive the engineering of improved variants. #biotech #proteinengineering #scienceiscool
Is ATUM’s machine learning approach a form of directed evolution? “We like to think of our platform more as directed engineering," Vice President of R&D Mark Welch tells Biocompare. "We determine the relationship between protein sequence and properties of interest and use that to drive engineering of improved variants." Don't miss this insightful piece exploring the role of directed evolution and directed engineering in protein engineering from Tiffany Yesavage, PhD! ? https://lnkd.in/gvVuAnsR #biotech #proteinengineering
Directed Evolution for Protein Engineering
biocompare.com
-
Congratulations to the Bone Health Technologies team!?With #FDA clearance, Osteoboost is one step closer to helping the nearly 52 Million Americans with low bone density (#osteopenia). Osteoboost is an innovative wearable belt device that delivers targeted, calibrated vibration to the lumbar spine and hips. Built on NASA-proven technology, Osteoboost offers a safe, medication-free, and easily deployable solution for patients with bone density loss. #MedTech #MedDevice?#ClientNews https://lnkd.in/ghjXXWkZ
Bone Health Technologies Announces FDA Clearance of OsteoboostTM, the First Prescription Medical Device to Treat Low Bone Density | BioSpace
biospace.com